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ABSTRACT 
Objective: Cobalamin deficiency may cause a lack of dietary methyl donors, which alter the heart metabolism. Cobalamin deficiency is common in 
patients with malnutrition, gastric ulcers, diabetes mellitus, and alcoholism. Most studies on cobalamin deficiency are focused on its relationship 
with oxidative stress and atherogenesis. Therefore, this study aims to find the correlation between cardiomyocyte’s energy metabolism in 
cobalamin deficiency and the risk of heart abnormalities through analysis of electrocardiography (ECG) patterns. 
Methods: Adult male Sprague-Dawley rats (aged 24-28 w) were divided into 2 groups: the control group and cobalamin-deficient group. The 
control group was given standard diet while the treatment group received a modified diet, type AIN-93M (deficient in cobalamin), for a period of 16 
w. ECG was performed in both groups on the last day of the 16-week period. Enzyme-linked immunosorbent assay (ELISA) test was also performed 
to evaluate plasma Hcy and B12 levels in each group at the end of the treatment period. 
Results: At the end of the 16-week period, higher Hcy level and lower plasma B12 level were observed in the treatment group when compared to 
the control group. ECG patterns showed sinus rhythms in both groups, with a higher QRS amplitude and duration in the treatment group. Two of the 
seven rats in the treatment group developed cardiac arrhythmia. 
Conclusions: Cobalamin deficiency impairs the heart’s energy metabolism with left ventricular enlargement and arrhythmia. 
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INTRODUCTION 
Heart failure (HF) is the terminal stage in cardiovascular disease, 
marked by the inability of the heart to pump blood with normal 
efficiency.1 In Asia, mortality and morbidity due to heart failure (HF) 
is still high [2]. In the ADHERE-AP (Asian-Pacific) Study, it was 
reported that HF patients registered in South-East Asia were 
generally younger (median age of 60 y for Indonesia) as compared 
with those in East Asia (median age of 77 y for both Hongkong and 
Taiwan) and in Australia (median age of 77 y). According to the data 
from Indonesia Basic Health Research (RISKESDAS) 2013, the 
prevalence of HF in Indonesia is at 0.13% for the total population of 
approximately 229, 696 people [1]. 
Most studies on cobalamin deficiencies are still focused on its 
relationship with oxidative stress and atherogenesis. Recent studies 
have shown the many classic risk factors for HF, such as smoking, 
hypertension, dyslipidemia, obesity, and diabetes mellitus [3]. One of 
the risk factors for HF is dietary intake imbalance. A recent study in 
nutrition and epigenomic/nutrigenomic reveald that some 
micronutrients are related to cardiovascular metabolism through 
epigenetic processes [4]. The micronutrients that may be involved in 
epigenetic processes are called methyl nutrients such as 
cobalamin/vitamin B12 [4, 5]. Methyl nutrients act as a source of 
methyl donors needed for DNA methylation, chromatin modification 
and various enzymatic reactions [4]. These epigenetic processes affect 
the activity in mitochondrial cardiomyocytes which regulates the 
heart’s energy metabolism [6, 7]. Thus, deficiency in cobalamin may 
lead to lack of dietary methyl donors, which will alter the heart 
metabolism [6, 7]. Cobalamin deficiency may also contribute to an 
increased plasma Hyc level (Hyc)/hyperhomocysteinemia [8]. 
Solomon et al. [8] observed that high levels of Hyc are related to 
oxidative stress, dyslipidemia, and atherogenesis. The prospective 
Framingham Heart Study observed that the incidents of congestive 
heart failure (CHF) almost double in individuals with a circulating Hyc 
concentration above the sex-specific median [9]. These conditions also 
may contribute to the risk factors and severity of HF [10]. 
The prevalence of cobalamin deficiency is high (about 20%) in many 
developing countries especially in Asia [11]. The populations 
susceptible to cobalamin deficiency are the elderly, pregnant and 
breastfeeding women, children, and young adults [11, 12]. In 
Indonesia, although there is no precise data about the prevalence of 
cobalamin deficiency, the risk is still high because most of its 
population of a low grade socio-economic status. This is related to 
the ability to consume meat and other foods with cobalamin content. 
The risk of B12 deficiency is also high in patients with chronic 
gastric ulcers who take a proton pump inhibitor as long-term 
therapy [13]. A recent study in endocrinology shows that patients 
with type 2 diabetes mellitus who use metformin as an oral 
hypoglycemic agents, especially at a higher dose and for a long 
duration, have developed a risk of cobalamin deficiency [14]. 
Functional cobalamin deficiency along with megaloblastic anemia is 
also found in alcohol-dependent patients [15]. 
This study aims to assess the correlation between cardiomyocyte’s 
energy metabolism in cobalamin deficiency and the risk of heart 
abnormalities through analysis of ECG patterns. We hypothesized 
that vitamin B12 deficiency cause’s hyperhomocysteinemia and 
induces abnormality of the heart’s electrical activity. 
MATERIALS AND METHODS 
Animals 
All experimental procedures using animals were approved by the 
medical research committee of Faculty of Medicine, Universitas 
Indonesia (219/UN2. FI/ETIK/2017). 
Fourteen adult male Sprague-Dawley rats aged 24-28 w (provided 
by The Research and Development division, Ministry of Health, 
Republic of Indonesia) were divided into 2 groups: the control group 
(C; n = 7) and cobalamin-deficient group (D; n 7). Both groups were 
maintained on a 12 light-dark cycle with free access to food and 
water. During a 16-week study period, the control group was given a 
standard diet type, AIN-93M (Harlan Teklad, USA) normal formula 
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while the treatment group received a modified diet based on the 
same food, AIN-93M but with cobalamin limited. To inhibit 
unintentional uptake of cobalamin, 5% per kg pectin was added to 
the modified deficient diet. The rats body weight and food 
consumption were monitored every month (every 4-week period). 
ECG 
ECG is a process to record the heart’s electrical activity in a period of 
time using electrodes on the skin [16]. These electrodes detect tiny 
changes in electrical currents from the heart muscles 
(depolarization and repolarization) during the heart’s contraction 
[16]. Abnormality in the heart’s energy metabolism will result in 
abnormal electrical conduction, which is expressed as an 
abnormality in ECG patterns. 
ECG was recorded in both groups on the last day of the 16-week 
period. Before the procedure was carried out, the rats were given 
intraperitoneal anesthesia with a combined dose of ketamine (100 
mg/kg) and xylazine (5 mg/kg). After anesthetization the rats were 
restrained on a square board using a small micropore adhesive tape. 
Electrodes used were acupuncture needles placed subcutaneously 
on four extremities, on the middle area of the chest and at the upper 
left axillary region (these ECG points represent lead measurements: 
I, II, III, aVL, aVR, aVF, V1, and V6). The ECG device used was type 
BTL-08 MT Plus (USA). 
Sample measurements 
Blood samples were taken at the beginning and end of the 16-week 
period. Blood was collected from the retrobulbar plexus/sinus orbitalis 
using a specialized cannula and then stored in the vacuette/vacutainer, 
which contained Ethylenediaminetetraacetic acid (EDTA) as an 
anticoagulant. Centrifugation was performed immediately at a speed 
of 3000 rpm for 15 min at room temperature and then plasma was 
collected by pipetting into a 1.5 ml microtube. The samples were 
stored at-80 °C until further analysis was performed. 
Plasma Hcy and cobalamin levels were quantified by direct competitive 
Enzyme-linked immunosorbent assay (ELISA) using polyclonal 
antibodies against Hyc and cobalamin, respectively. The reagents used 
were MBS766209 and MBS731816 (MyBioSource, USA). Intra and 
inter-assay CVs of the Hcy ELISA were<8% and<10%, respectively. 
Both CVs of the B12 ELISA were<10%. Quality control materials 
recommended by the manufacturers were used for all samples. 
Statistical analyses 
Body weight, plasma Hcy, plasma B12, the heart rate, and RS 
amplitude were analyzed using a t-test (independent t-test for 
analysis between groups and paired t-test for analysis within a 
group). The corrected QT interval (QTc) and QRS-T angle were 
analyzed using a Mann-Whitney test. All data were analyzed with 
SPSS 21.0 statistic software for Windows (SPSS Inc., USA). 
 
RESULTS 
Table 1: Experimental group characteristics at the beginning and end of the study 
Variable Control Deficient 
C C16 0 D D16 0 
Number of samples 7 7 7 7 
Body weight (g) 295.71±6.50 379.43±18.28 303.29±10.56 a 363.00±17.94
Hcy (µmol/l) 
b 
250.14±27.81 253.07±28.16 416.80±209.77 842.90±373.58
B12 (ng/l) 
b,c 
425.60±68.46 405.51±67.43 654.24±133.88a 388.26±113.29c b 
Data are mean±SD. a **p<0.001 vs C0; b **p<0.01 vs D0;  c **p<0.01 vs C
 
Body weight 
At the beginning of the study, the body weight of both the control 
group and treatment group was statistically homogenous. During 
the 16-week feeding period, both groups exhibited a significant 
gain in body weight (C0 vs C16, **p<0.001; D0 vs D16, **p<0.001) 
but no significant weight difference was observed between groups 
(table 1). 
16 
Plasma Hcy and B12 levels 
All animals in the treatment group showed a significant increase in 
plasma Hcy concentration (D16 vs D0, p<0.01; D16 vs C16, 
**p<0.01) (table 1) and a significant decrease in plasma B12 
concentration (D16 vs D0, **p<0.001) compared to the control 
group. This condition shows the efficacy of the vitamin deficient 
model used in this study. Nevertheless, the control group also had a 
significant decrease in plasma B12 levels (C0 vs C16, **p<0.001). 
  
Table 2: Characteristics of ECG after 16 w of treatment 
Variable Control Deficient 
(C) (D) 
Heart rate (pulse/min) 255.89±38.15 264.76±38.51 
QTc (ms) 0.10±0.01 0.16±0.02* 
RS Amplitude (mV) 1.11±0.45 2.38±1.47 
QRS-T angle (degree) 19.84±23.13 58.71±50.59* 
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Fig. 1: Arrhythmia in the treatment group 
 
ECG 
In this study, four parameters of ECG that represented the activity of 
left ventricle were examined: (1) Heart Rate, (2) QTc, (3) RS 
amplitude, and (4) QRS-T angle. After a 16-week B12 deficient period, 
no significant increase in the heart rate was observed, whereas the 
QTc significantly increased (D vs C, *p<0.05), the RS amplitude 
increased, although significantly, and the QRS-T angle significantly 
increased (D vs C, *p<0.05) (table 2). We also observed that two of the 
seven rats in the treatment group develop cardiac arrhythmias (fig. 1). 
DISCUSSION 
The results from this study show that weight gain in both the control 
group and treatment group after a 16-week study period was 
consistent with normal growth and development in average 
Sprague-Dawley rats. Increasing body weight is closely related to 
advancing age (from “weaning” to “old”) until the rats enter a 
senescence period, when the body mass starts to decrease [17, 18]. 
According to the results in this study, feeding rats with either a 
standard or cobalamin-deficient diet did not affect their weight gain. 
Cobalamin is a cofactor that acts as a methyl donor for methionine 
synthase in the methionine cycle [4, 5, 19]. Cobalamin deficiency 
might impair conversion of Hyc to methionine. Thus, the 
concentration of Hyc will increase [5, 19]. In this study, we found a 
statistically significant increase in plasma Hcy concentrations both 
within the treatment group and between the two groups. These 
findings are consistent with previous studies on cobalamin which 
show that deficiency in cobalamin will induce 
hyperhomocysteinemia [20, 21]. 
Measuring plasma or serum cobalamin levels is a gold standard 
method to determine if a patient is suffering from cobalamin 
deficiency [22, 23]. There are many causes of cobalamin as such as a 
Helicobacter pylori infection, low dietary intancbike, gastric 
malabsorption, and genetic disorders that may result in a low 
plasma cobalamin concentration [22]. In this study, we found that 
plasma B12 concentrations in the treatment group was significantly 
decreased. This result is also consistent with previous studies, which 
states that one of the causes of cobalamin deficiency is low dietary 
intake and malabsorption (considering the addition of 5% pectin to 
inhibit unintentional uptake of cobalamin). Meanwhile within the 
control group, plasma B12 concentration also significantly 
decreased. This result seemed contradictory because the diet given 
was standard with no cobalamin deficiency. Even though the plasma 
B12 levels between the treatment group and the control group was 
not statistically significant at the end of the treatment, the plasma 
B12 levels in the treatment groups were still lower than those of the 
control group (plasma B12 levels in the control group decreased 
20.11 pg/ml, while plasma B12 levels in the treatment group 
decreased 265.98 pg/ml). 
ECG was performed to assess the heart’s electrical activity. There 
were four parameters examined in this study. The first parameter 
was heart rate, in which there was no significant difference between 
the control group and treatment group. It seems that, diet does not 
affect heart rate specifically. The normal range of heart rate in adult 
Sprague-Dawley rats is 330-480 beats/min [24]. In this study, the 
heart rate in both groups was lower than normal. These findings are 
consistent with a previous study, in which a combination dose of 
ketamine-xylazine (±100 mg/kg and±5 mg/kg) decreased the heart 
rate [24]. Two of the seven rats in the treatment group developed 
cardiac arrhythmia. These findings are in line with another study, in 
which high levels of Hcy/hyperhomocysteinemia impaired the 
heart’s electrical conductivity [25, 26]. 
The second parameter examined was the QTc. QTc is a measure of 
the combination of cardiac depolarization and repolarization as it 
encompasses both the QRS complex and the J-T interval [27]. 
Ventricular conduction delay is also often associated with (to a 
lesser degree) lengthening of the QT interval [27]. This study shows 
that QTc interval in the treatment group was significantly higher 
when compared to the control group. We may suggest that in the 
treatment group, the process of depolarization-repolarization was 
disturbed and might have resulted in delayed ventricular 
conduction. The most probable explanation was that high levels of 
Hyc induced the heart remodeling process. Delayed ventricular 
conduction is the first sign to appear in the heart muscle 
hypertrophy. This study result supports the pathophysiologic 
mechanism in cardiac hypertrophy related to 
hyperhomocysteinemia [28, 29]. 
The third parameter examined was the RS amplitude. The RS 
amplitude is an integral part of the QRS complex and it represents 
electrical activities in the heart’s ventricles (especially left ventricle) 
[30]. Previous studies stated that the RS amplitude is closely related 
to the risk of developing hypertrophic cardiomyopathy; the higher 
the RS amplitude, the higher the risk of developing hypertrophic 
cardiomyopathy [30]. We did not observe any significant increase in 
the RS amplitude in the treatment group. However, we observed the 
tendency of increasing RS amplitude in the treatment group. 
According to this phenomenon, we believe the treatment group was 
in the process of developing minor hypertrophic cardiomyopathy. 
Future research with a longer study period is needed to confirm this 
theory. 
The fourth parameter examined was the QRS-T angle. By ECG, one 
can measure a spatial angle between depolarization and 
repolarization, specifically an angle between the QRS vector and T 
vector, namely spatial QRS-T angle [31]. In previous studies, QRS-T 
angle has been shown to predict ventricular arrhythmia [32]. In this 
study, the treatment group showed a significant increase in the QRS-
T angle. This result is in line with a previous study, as evident in the 
arrhythmia developed by two of the seven deficient rats. The 
probable mechanism in this finding is related to 
hyperhomocysteinemia-induced the heart electrical impairment and 
is closely related to the possibility of cardiac hypertrophy. In 
conclusion, this study showed that cobalamin deficiency impairs the 
heart’s energy metabolism with left ventricular enlargement and 
arrhythmia. 
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